Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06421155 · ClinicalTrials.gov registry record · NA
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
A NA study of Myeloproliferative Neoplasm and Acute Leukemia, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06421155: Recruiting NA study of Myeloproliferative Neoplasm and Acute Leukemia, sponsored by Case Comprehensive Cancer Center.
NCT06421155 is a NA study of Myeloproliferative Neoplasm and Acute Leukemia that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 20 participants, below the 84-participant average among 40 other Myeloproliferative Neoplasm trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06421155, a NA study of Myeloproliferative Neoplasm and Acute Leukemia, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The survival of children, adolescents and young adults (AYA) with acute leukemia has improved dramatically over the last two decades. This success is a result of using multiple chemotherapy drugs in combination, with the inclusion of drugs that enter the brain and prevent leukemia cells from growing there. Studies in these cancer survivors have shown that the exposure to these chemotherapy drugs can lead to risks for impaired brain function, also referred to as neurocognitive side effects of chemotherapy. There is an opportunity to identify participants at risk for these side effects and to prevent their development. The purpose of this study is to incorporate a brain imaging tool known as Magnetic Resonance Fingerprinting (MRF) to look for brain matter changes in acute leukemia participants receiving chemotherapy. The MRF scan will be performed at diagnosis and repeated at multiple times during the entire therapy duration as well as at defined intervals after therapy is complete. Investigators would also do an electronic test of memory and brain function (cognitive function), which would be administered in a gaming format on iPads or a similar device. The goal will be to correlate results of MRF imaging with the tests of cognitive function. The benefits of this imaging technique include that it can be done quickly (in minutes), it is non-invasive, it is resistant to motion-artifacts and it can be easily repeated for comparison purposes. The advantages of the cognitive test include its short duration of 20 minutes and its gaming format making it friendly for children to use.
Conditions Studied
Interventions
- OTHER MRF with neurocognative studies
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center, Rainbow Babies & Children's Hospital, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-04 |
| Est. Completion | 2028-06-14 |
| Phase | NA |
What NCT06421155 shows while recruiting
NCT06421155 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 84-participant average among 40 other Myeloproliferative Neoplasm trials with a reported enrollment target (76% lower).
The record links to 4 conditions, with Myeloproliferative Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which MRF with neurocognative studies is the first listed.
NCT06421155 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06421155 about?
NCT06421155 is a clinical study titled "Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia". The survival of children, adolescents and young adults (AYA) with acute leukemia has improved dramatically over the last two decades. This success is a result of using multiple chemotherapy drugs in combination, with the inclusion of drugs that enter the brain and prevent leukemia cells from growing...
What is the current status of trial NCT06421155?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-10-04. Estimated completion is 2028-06-14.
What conditions does trial NCT06421155 study?
This clinical trial studies the following conditions: Myeloproliferative Neoplasm, Acute Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Acute Myeloid Leukemia in Children.
What interventions are being tested in trial NCT06421155?
The interventions under investigation include: MRF with neurocognative studies (OTHER).
Who is sponsoring clinical trial NCT06421155?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06421155 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloproliferative Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06421155's enrollment target sits among peer trials
20 36th of 40 higher than 4 of 40 other Myeloproliferative Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloproliferative Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
RECRUITING · NA
-
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
RECRUITING · NA
-
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
ACTIVE NOT RECRUITING · NA
-
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
COMPLETED · NA
-
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
COMPLETED · NA
-
A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI